Aberdeen Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$654K Hold
711
0.3% 71
2025
Q4
$764K Sell
711
-65
-8% -$62.2K 0.35% 62
2025
Q3
$592K Hold
776
0.37% 76
2025
Q2
$605K Hold
776
0.4% 71
2025
Q1
$641K Hold
776
0.44% 72
2024
Q4
$599K Hold
776
0.41% 73
2024
Q3
$687K Sell
776
-79
-9% -$71K 0.45% 66
2024
Q2
$774K Hold
855
0.52% 50
2024
Q1
$665K Sell
855
-100
-10% -$71.2K 0.39% 72
2023
Q4
$557K Hold
955
0.4% 77
2023
Q3
$513K Hold
955
0.39% 74
2023
Q2
$448K Hold
955
0.32% 90
2023
Q1
$328K Sell
955
-65
-6% -$21.9K 0.24% 107
2022
Q4
$373K Hold
1,020
0.28% 102
2022
Q3
$330K Hold
1,020
0.29% 98
2022
Q2
$331K Hold
1,020
0.26% 101
2022
Q1
$292K Hold
1,020
0.2% 124
2021
Q4
$282K Hold
1,020
0.18% 119
2021
Q3
$236K Hold
1,020
0.23% 111
2021
Q2
$234K Buy
+1,020
New +$205K 0.22% 116
2021
Q1
Sell
-1,193
Closed -$201K 151
2020
Q4
$201K Buy
+1,193
New +$178K 0.15% 134
2020
Q3
Sell
-1,343
Closed -$220K 139
2020
Q2
$220K Buy
+1,343
New +$206K 0.24% 114

Other funds holding LLY

Aberdeen Wealth Management's LLY Position: Q1 2026 in Review

Aberdeen Wealth Management held its Eli Lilly (LLY) position steady in Q1 2026 at 711 shares worth $654K. The position accounts for 0.3% of the portfolio, ranked #71.

Aberdeen Wealth Management first reported a position in LLY in Q2 2020 and has held it in 22 quarters since. The position peaked at $774K in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Aberdeen Wealth Management held 711 shares of Eli Lilly worth $654K as of Q1 2026.
  • Aberdeen Wealth Management left its Eli Lilly share count unchanged in Q1 2026.
  • Eli Lilly made up 0.3% of Aberdeen Wealth Management's portfolio in Q1 2026, its #71 holding.
  • Aberdeen Wealth Management first reported a position in Eli Lilly in Q2 2020 and has held it in 22 quarters since.
  • Aberdeen Wealth Management's Eli Lilly position peaked at $774K in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Aberdeen Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.